{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cell+therapy&page=2",
    "query": {
      "intervention": "cell therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 12411,
    "total_pages": 1242,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cell+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cell+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T02:40:18.890Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05498220",
      "title": "Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Polatuzumab vedotin (PV)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "GCSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-02-17",
      "completion_date": "2025-10-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498220"
    },
    {
      "nct_id": "NCT00957424",
      "title": "Acceptability of Less Harmful Alternatives to Cigarettes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer",
        "Cervical Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Liver Cancer",
        "Lung Cancer",
        "Pancreatic Cancer",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "nicotine replacement therapy",
          "type": "DRUG"
        },
        {
          "name": "informational intervention",
          "type": "OTHER"
        },
        {
          "name": "internet-based intervention",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 67,
      "start_date": "2009-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957424"
    },
    {
      "nct_id": "NCT00907413",
      "title": "Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "ERCP and Photodynamic Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "ERCP only",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2010-05",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Charlotteville, Virginia",
      "locations": [
        {
          "city": "Charlotteville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00907413"
    },
    {
      "nct_id": "NCT05647213",
      "title": "Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Univentricular Heart",
        "Congenital Heart Disease",
        "Heart Failure NYHA Class III",
        "Heart Failure NYHA Class IV"
      ],
      "interventions": [
        {
          "name": "iPSC-CL",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "HeartWorks, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-02-03",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05647213"
    },
    {
      "nct_id": "NCT07297160",
      "title": "CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Solid Tumors",
        "Sarcoma",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Level -1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 1 (starting dose level)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "0 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-06",
      "completion_date": "2044-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07297160"
    },
    {
      "nct_id": "NCT04109482",
      "title": "Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"
      ],
      "interventions": [
        {
          "name": "MB-102",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustang Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-02-17",
      "completion_date": "2023-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-07-22",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04109482"
    },
    {
      "nct_id": "NCT01408160",
      "title": "Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult B Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2013-04",
      "completion_date": "2018-06-26",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 2,
      "location_summary": "The Bronx, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408160"
    },
    {
      "nct_id": "NCT04185220",
      "title": "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult T-Cell Lymphoma/Leukemia",
        "Sezary Syndrome",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Recombinant human Interleukin-15 (rhIL-15)",
          "type": "DRUG"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-02-26",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04185220"
    },
    {
      "nct_id": "NCT00201682",
      "title": "Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Byrd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2002-10",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201682"
    },
    {
      "nct_id": "NCT00511576",
      "title": "Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Pulmonary Cancer",
        "Non-Small-Cell Lung Carcinoma",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Gastric Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "MGCD0103 & Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2007-08",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-10-07T02:40:18.890Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511576"
    }
  ]
}